



Product Specification Sheet

Product Name: ONO-7475

Catalog Number: C6667

Technical information:

Chemical Formula: $C_{32}H_{26}N_4O_6$

CAS #: 1646839-59-9

Molecular Weight: 562.57

Purity: > 98%


Appearance: Off-white solid

Solubility: Soluble in DMSO up to 177 mM

Chemical Name: N-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide

Storage: For longer shelf life, store solid powder or DMSO solution at -20°C desiccated.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



- Handling:**
- To make 10 mM stock solution, add 0.178mL of DMSO for each mg of ONO-7475 .
 - For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

Biological Activity: ONO-7475 is a potent inhibitor of Anexelekto(Axl)/MER tyrosine kinase with IC50 at nM range for both AXL and MER. AXL has been implicated in diverse tumor-promoting processes such as proliferation, migration, invasion, survival, and apoptosis, and therefore considered a promising druggable target to overcome drug resistance for acute myeloid leukemia, pancreatic cancer [2], lung cancer [3], as well as breast cancer [3]. ONO-7475 sensitizes and suppresses the emergence of tolerant cells to the initial EGFR-TKIs, osimertinib or dacomitinib, in AXL-overexpressing EGFR-mutated NSCLC cells, suggesting that ONO-7475 and osimertinib is a highly potent combination for initial treatment of NSCLC.

- Reference:**
1. Post SM, et al. AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells. Blood 2019; 134 (Supplement_1): 2550. Pubmed ID: doi.org/10.1182/blood-2019-128626
 2. Du W, et al. Does Axl have potential as a therapeutic target in pancreatic cancer? Expert Opin Ther Targets 2018; 22(11):955-966. Pubmed ID: 30244621
 3. Okura N, et al. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. Clin Cancer Res 2020;26:2244-56. Pubmed ID: 31953310

To reorder: <http://www.cellagentech.com/ONO-7475/>

For Technical Support: technical@cellagentech.com

Chemicals are sold for research use only, not for clinical or diagnostic use.